Search

Your search keyword '"Ana Y, Carbajo"' showing total 13 results
Start Over Author "Ana Y, Carbajo"
13 results on '"Ana Y, Carbajo"'

2. 49 - PREDICCIÓN DEL RIESGO FARMACOGENÉTICO DE PANCREATITIS AGUDA POR TIOPURINAS EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL: ESTUDIO CASO-CONTROL BASADO EN EL REGISTRO ENEIDA

Author

Iván Guerra, Francisco Barros, María Chaparro, José M. Benítez, María Dolores Martín Arranz, Ruth de Francisco, Marta Piqueras, Luisa de Castro, Ana Y. Carbajo, Fernando Bermejo, Miguel Mínguez, Ana Gutiérrez, Francisco Mesonero, Fiorella Cañete, Carlos González-Muñoza, Marta Calvo, Beatriz Sicilia, Erika Alfambra, Carlos A. Tardillo, Montserrat Rivero, Alfredo J. Lucendo, Luis Bujanda, Manuel van Domselaar, Pedro Almela, Laura Ramos, María Fernández Sánchez, Esther Hinojosa, Cristina Verdejo, Anna Gimenez, Iago Rodríguez-Lago, Noemí Manceñido, José L. Pérez Calle, Mónica del Pilar Moreno, Pedro Genaro Delgado- Guillena, Beatriz Antolín, Patricia Ramírez de la Piscina, M.J. Casanova, Pilar Soto Escribano, Eduardo Martín Arranz, Isabel Pérez Martínez, Raquel Mena, Natalia García Morales, Alicia Granja, Marta Maia Bosca Watts, Rubén Francés, Cristina Fernández, Margalida Calafat, Cristina Roig-Ramos, María Isabel Vera Mendoza, Ángel Carracedo, Eugeni Domènech, and Javier P. Gisbert

Subjects
Hepatology, Gastroenterology
Published
2023
Full Text
View/download PDF

4. Clinical Review of EUS-guided Gastroenterostomy (EUS-GE)

Author

Ana Y Carbajo, Michel Kahaleh, and Amy Tyberg

Subjects
Endoscopic ultrasound, medicine.medical_specialty, medicine.medical_treatment, Self Expandable Metallic Stents, Enteral administration, Endosonography, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Symptom relief, medicine, Humans, Adverse effect, Ultrasonography, Interventional, medicine.diagnostic_test, Gastric Outlet Obstruction, business.industry, Gastroenterology, Stent, Gastric outlet obstruction, medicine.disease, Gastroenterostomy, digestive system diseases, Surgery, Treatment Outcome, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, business
Abstract

Gastric outlet obstruction (GOO) refers to mechanical obstruction of the distal stomach or proximal duodenum and it is associated with a significant decrease in quality of life. Surgical gastrojejunostomy and self-expandable metal stents were the traditional treatment for GOO. Recently, endoscopic ultrasound guided gastroenterostomy (EUS-GE) has emerged as a third therapeutic option for patients with GOO. Most EUS-GE techniques utilize the placement of a lumen-apposing metal stent under echoendoscopy but differ in the method of localizing the jejunal loop prior to EUS puncture. Data supporting EUS-GE have been promising. Case series including 10 or more cases showed the technical success rate to be approximately 90%. Clinical success is achieved in approximately 85-90% and a less than 18% risk of adverse events is reported. EUS-GE was associated with a lower recurrence of GOO and need for re-intervention when compared to enteral stenting. In addition, EUS-GE shows significantly fewer adverse events compared with surgical gastrojejunostomy. In conclusion, EUS-GE provides symptom relief without the risks of surgical intervention and the limited patency of enteral SEMS placement. EUS-GE is an exciting new option in the management of GOO. Despite the excellent results, randomized studies comparing these different modalities of treatment for GOO are needed before EUS-GE can be accepted as standard of care.

Published
2019
Full Text
View/download PDF

6. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

Author

María Chaparro, Ana Garre, Marisa Iborra, Mónica Sierra-Ausín, Manuel Barreiro-de Acosta, Agnès Fernández-Clotet, Luisa de Castro, Maia Boscá-Watts, María José Casanova, Alicia López-García, Rufo Lorente, Cristina Rodríguez, Ana Y Carbajo, Maria Teresa Arroyo, Ana Gutiérrez, Joaquín Hinojosa, Teresa Martínez-Pérez, Albert Villoria, Fernando Bermejo, David Busquets, Blau Camps, Fiorella Cañete, Noemí Manceñido, David Monfort, Mercè Navarro-Llavat, José Lázaro Pérez-Calle, Laura Ramos, Montserrat Rivero, Teresa Angueira, Patricia Camo Monterde, Daniel Carpio, Irene García-de-la-Filia, Carlos González-Muñoza, Luis Hernández, José M Huguet, Víctor J Morales, Beatriz Sicilia, Pablo Vega, Isabel Vera, Yamile Zabana, Pilar Nos, Patricia Suárez Álvarez, Cristina Calviño-Suárez, Elena Ricart, Vicent Hernández, Miguel Mínguez, Lucía Márquez, Daniel Hervías Cruz, Saioa Rubio Iturria, Jesús Barrio, Carla Gargallo-Puyuelo, Rubén Francés, Esther Hinojosa, María del Moral, Xavier Calvet, Alicia Algaba, Xavier Aldeguer, Jordi Guardiola, Miriam Mañosa, Ramón Pajares, Marta Piqueras, Orlando García-Bosch, Pilar López Serrano, Beatriz Castro, Alfredo J Lucendo, Miguel Montoro, Elena Castro Ortiz, Francisco Mesonero, Esther García-Planella, David A Fuentes, Inmaculada Bort, Pedro Delgado-Guillena, Lara Arias, Agueda Iglesias, Marta Calvo, Maria Esteve, Eugeni Domènech, and Javier P Gisbert

Subjects
Male, medicine.medical_specialty, ustekinumab, Vedolizumab, 03 medical and health sciences, 0302 clinical medicine, remission, Colitis ulcerosa, Internal medicine, Ustekinumab, Humans, Medicine, Prospective Studies, Registries, Infusions, Intravenous, Adverse effect, real-world evidence, AcademicSubjects/MED00260, ulcerative colitis, Tofacitinib, response, biology, business.industry, Remission Induction, C-reactive protein, Gastroenterology, General Medicine, Middle Aged, medicine.disease, Ulcerative colitis, Discontinuation, 030220 oncology & carcinogenesis, Cohort, biology.protein, durability, Original Article, Colitis, Ulcerative, Female, Monoclonal antibodies, 030211 gastroenterology & hepatology, business, Anticossos monoclonals, medicine.drug
Abstract

Background and Aims The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life. Methods Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16. Results A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% of patients in remission]. In the multivariate analysis, elevated serum C-reactive protein was the only variable significantly associated with lower likelihood of achieving remission. Remission was achieved in 39% and 33% of patients at Weeks 24 and 52, respectively; 36% of patients discontinued the treatment with ustekinumab during a median follow-up of 31 weeks. The probability of maintaining ustekinumab treatment was 87% at Week 16, 63% at Week 56, and 59% at Week 72; primary failure was the main reason for ustekinumab discontinuation. No variable was associated with risk of discontinuation. Three patients reported adverse events; one of them had a fatal severe SARS-CoV-2 infection. Conclusions Ustekinumab is effective in both the short and the long term in real life, even in a highly refractory cohort. Higher inflammatory burden at baseline correlated with lower probability of achieving remission. Safety was consistent with the known profile of ustekinumab.

Published
2021

7. Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry

Author

Marisa, Iborra, Belén, Beltrán, Agnes, Fernández-Clotet, Eva, Iglesias-Flores, Pablo, Navarro, Montserrat, Rivero, Ana, Gutiérrez, Mónica, Sierra-Ausin, Francisco, Mesonero, Rocío, Ferreiro-Iglesias, Joaquín, Hinojosa, Xavier, Calvet, Beatriz, Sicilia, Carlos, González-Muñoza, Beatriz, Antolín, María, González-Vivo, Ana Y, Carbajo, Santiago, García-López, Albert, Martín-Cardona, Gerard, Surís, María Dolores, Martin-Arranz, Ruth, de Francisco, Fiorella, Cañete, Eugeni, Domènech, Pilar, Nos, and D, Casas-Deza

Subjects
Adult, Male, medicine.medical_specialty, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Refractory, Ileum, Internal medicine, Ustekinumab, Humans, Medicine, Pharmacology (medical), In patient, Registries, 030212 general & internal medicine, Adverse effect, Retrospective Studies, Crohn's disease, Hepatology, Tumor Necrosis Factor-alpha, business.industry, Maintenance dose, Remission Induction, Endoscopy, Middle Aged, medicine.disease, Faecal calprotectin, C-Reactive Protein, Multicenter study, Female, 030211 gastroenterology & hepatology, business, Leukocyte L1 Antigen Complex, medicine.drug
Abstract

Background Data on the long-term administration of ustekinumab in recommended doses are limited. Aim To assess the real-world, long-term effectiveness of ustekinumab in refractory Crohn's disease (CD). Methods Multicenter study of CD patients starting ustekinumab at the recommended dose, followed for 1 year. Values for the Harvey-Bradshaw Index (HBI), endoscopic activity, C-reactive protein (CRP), and faecal calprotectin (FC) were recorded at baseline and at weeks 26 and 52. Demographic and clinical data, previous treatments, adverse events (AEs) and hospitalisations were documented. Potential predictors of remission were examined. Results A total of 407 patients were analysed. The initial maintenance dose of 90 mg SC was administered every 12, 8 and 4 weeks in 56 (14%), 347 (85%) and 4 (1%) patients, respectively. After 52 weeks, treatment was discontinued in 112 patients (27.5%). At baseline, 295 (72%) had an HBI >4 points. Of these, 169 (57%) and 190 (64%) achieved clinical remission at weeks 26 and 52, respectively. FC levels returned to normal in 44% and 54% of patients at weeks 26 and 52, and CRP returned to normal in 36% and 37% of patients at weeks 26 and 52, respectively. AEs were recorded in 60 patients. The use of fewer previous anti-TNFα agents and ileal localisation were associated with clinical remission, and endoscopic severity was associated with poor response. No factors correlated with endoscopic remission. Conclusion After 52 weeks, ustekinumab demonstrated effectiveness to induce clinical and endoscopic remission with safety in patients with refractory CD.

Published
2020
Full Text
View/download PDF

8. Mo1860 REAL-WORLD LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN CROHN'S DISEASE: RESULTS FROM THE ENEIDA REGISTRY

Author

Iborra, Marisa, primary, Beltran, Belen, additional, Fernández-Clotet, Agnes, additional, Flores, Eva Iglesias, additional, Cortes, Pablo Navarro, additional, Rivero, Montserrat, additional, Gutiérrez, Ana, additional, Sierra-Ausin, Monica, additional, Mesonero, Francisco, additional, Ferreiro, Rocio, additional, Hinojosa, Joaquin, additional, Calvet, Xavier, additional, Sicilia, Beatriz, additional, González-Muñosa, Carlos, additional, Antolín, Beatriz, additional, Gonzalez, Maria, additional, López, Ana Y. Carbajo, additional, García-López, Santiago, additional, Cardona, Albert Martin, additional, Surís, Gerard, additional, Arranz, Maria Dolores A. Martín, additional, De Francisco, Ruth M., additional, Cañete, Fiorella, additional, Samso, Carlos Taxonera, additional, Gomollon, Fernando, additional, Lorente, Rufo, additional, Rodríguez-Lago, Iago, additional, Fores-Bosh, Ana, additional, Bernardos, Esther, additional, Ramos, Laura, additional, Delgado-Guillena, Pedro, additional, Camba, Alejandro Hernandez, additional, Van Domselaar, Manuel, additional, Hervás, David, additional, Domènech, Eugeni, additional, and Nos, Pilar, additional

Published
2020
Full Text
View/download PDF

9. Tu1904 USE OF MYCOPHENOLATE MOFETIL IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM ENEIDA REGISTRY

Author

Camba, Alejandro Hernandez, primary, Hernández, Laura Arranz, additional, Vera, Isabel, additional, Carpio, Daniel, additional, Calafat, Margalida, additional, Lucendo, Alfredo, additional, Samso, Carlos Taxonera, additional, Pedrosa, Sandra Marín, additional, Garcia, María José, additional, Surís, Gerard, additional, Rodríguez, Eugenia Sánchez, additional, López, Ana Y. Carbajo, additional, De Castro, Luisa, additional, Iborra, Marisa, additional, Cardona, Albert Martin, additional, Rodríguez-Lago, Iago, additional, Busquets, David, additional, Bertoletti, Federico, additional, Sierra-Ausin, Monica, additional, Tardillo, Carlos, additional, Huguet, José María, additional, Bujanda, Luis, additional, Castano, Andres, additional, Ochoa, Olga Merino, additional, Domènech, Eugeni, additional, and Ramos, Laura, additional

Published
2020
Full Text
View/download PDF

10. Tu1904 USE OF MYCOPHENOLATE MOFETIL IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM ENEIDA REGISTRY

Author

Monica Sierra-Ausin, Laura Arranz Hernández, Iago Rodríguez-Lago, Marisa Iborra, José María Huguet, Albert Martin Cardona, Luísa Castro, G Suris, David Busquets, Andres Castano, Isabel Vera, Carlos Tardillo, Sandra Marín Pedrosa, Alejandro Hernandez Camba, Federico Bertoletti, Eugeni Domènech, Daniel Carpio, Carlos Taxonera Samso, Laura Ramos, Eugenia Sánchez Rodríguez, María José Garcia, Luis Bujanda, Ana Y. Carbajo López, Alfredo J. Lucendo, M Calafat, and Olga Merino Ochoa

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, business, Mycophenolate, medicine.disease, Inflammatory bowel disease
Published
2020
Full Text
View/download PDF

11. Su1865 – Real-World Short-Term Effectivenes of Ustekinumab in Crohn’s Disease: Results from the Eneida Registry

Author

Iborra, Marisa, primary, Beltran, Belen, additional, Fernández-Clotet, Agnes, additional, Gutiérrez, Ana, additional, Antolín, Beatriz, additional, Huguet, José María, additional, de Francisco, Ruth, additional, Merino-Ochoa, Olga, additional, Carpio, Daniel, additional, García-López, Santiago, additional, Mesonero, Francisco, additional, Mínguez, Miguel, additional, Ferreiro, Rocio, additional, López, Ana Y. Carbajo, additional, Rivero, Montserrat, additional, Chaparro, María, additional, Piñero-Pérez, M. Concepción, additional, Miquel, David Monfort i, additional, Bujanda, Luis, additional, García-Sepulcre, Mariana Fe, additional, Cardona, Albert Martin, additional, Cañete, Fiorella, additional, Taxonera, Carlos, additional, Sierra-Ausin, Monica, additional, Ferrer-Rosique, Juan A., additional, Martín-Arranz, MD, additional, González-Muñosa, Carlos, additional, Marcos, Noemí Manceñido, additional, Rodríguez-Lago, Iago, additional, Flores, Eva Iglesias, additional, Fores-Bosh, Ana, additional, Navarro-Llavat, Merce, additional, Calafat, Margalida, additional, Madrigal-Domínguez, Rosa E., additional, Ramos, Laura, additional, Arroyo, Maite, additional, Busquets, David, additional, Lorente, Rufo, additional, Sainz-Arnau, Empar, additional, Camba, Alejandro Hernandez, additional, Morales, Victor Jair, additional, Paredes, Jose María, additional, Van Domselaar, Manuel, additional, Hervás, David, additional, Cañada, Antonio, additional, and Nos, Pilar, additional

Published
2019
Full Text
View/download PDF

12. Su1865 – Real-World Short-Term Effectivenes of Ustekinumab in Crohn’s Disease: Results from the Eneida Registry

Author

Carlos González-Muñosa, Daniel Carpio, Pilar Nos, Luis Bujanda, Carlos Taxonera, Ana Gutiérrez, Martín-Arranz, Santiago García-López, David Monfort i Miquel, Ruth de Francisco, Juan A. Ferrer-Rosique, Monica Sierra-Ausin, Albert Martin Cardona, Belén Beltrán, Ana Fores-Bosh, Montserrat Rivero, Iago Rodríguez-Lago, José María Paredes, M. Concepción Piñero-Pérez, Rosa E. Madrigal-Domínguez, Marisa Iborra, Miguel Minguez, Maite Arroyo, David Busquets, M F García-Sepulcre, Empar Sainz-Arnau, Laura Ramos, M Calafat, José María Huguet, Francisco Mesonero, Noemí Manceñido Marcos, Victor J. Morales, Manuel Van Domselaar, Fiorella Cañete, M Navarro-Llavat, Rocío González Ferreiro, Antonio Cañada, Olga Merino-Ochoa, Ana Y. Carbajo López, María Chaparro, Eva Iglesias Flores, Agnès Fernández-Clotet, Beatriz Antolín, Rufo Lorente, Alejandro Hernandez Camba, and David Hervás

Subjects
Crohn's disease, Pediatrics, medicine.medical_specialty, Hepatology, business.industry, Ustekinumab, Gastroenterology, Medicine, business, medicine.disease, Term (time), medicine.drug
Published
2019
Full Text
View/download PDF

13. REAL-WORLD SHORT-TERM EFFECTIVENES OF USTEKINUMAB IN CROHN'S DISEASE: RESULTS FROM THE ENEIDA REGISTRY

Author

Iborra, Marisa, Beltran, Belen, Fernandez-Clotet, Agnes, Gutierrez, Ana, Antolin, Beatriz, Huguet, Jose Maria, Francisco, Ruth, Merino-Ochoa, Olga, Carpio, Daniel, Garcia-Lopez, Santiago, Mesonero, Francisco, Minguez, Miguel, Ferreiro, Rocio, Lopez, Ana Y. Carbajo, Rivero, Montserrat, Chaparro, Maria, Pinero-Perez, M. Concepcion, Monfort I Miquel, David, Luis Bujanda, Garcia-Sepulcre, Mariana Fe, Cardona, Albert Martin, Canete, Fiorella, Taxonera, Carlos, Sierra-Ausin, Monica, Ferrer-Rosique, Juan A., Martin-Arranz, M. D., Gonzalez-Munosa, Carlos, Marcos, Noemi Mancenido, Rodriguez-Lago, Iago, Flores, Eva Iglesias, Fores-Bosh, Ana, Navarro-Llavat, Merce, Calafat, Margalida, Madrigal-Dominguez, Rosa E., Ramos, Laura, Arroyo, Maite, Busquets, David, Lorente, Rufo, Sainz-Arnau, Empar, Camba, Alejandro Hernandez, Morales, Victor Jair, Paredes, Jose Maria, Domselaar, Manuel, Hervas, David, Canada, Antonio, and Nos, Pilar

Catalog

Books, media, physical & digital resources
See catalog results